Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
JERSEY CITY, N.J., Aug. 31, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences:
- The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesday, September 7, 2016 at 4:20 p.m. ET.
- The 23rd Annual NewsMakers in the Biotech Industry Investment Conference at the Millennium Broadway in New York on Friday, September 9, 2016 at 9:30 a.m. ET.
- The Aegis Growth Conference at the Wynn Las Vegas on Thursday, September 22, 2016 at 9:00 a.m. PT.
Live webcasts of the presentations will be available on the investors section of the Company's website: www.SCYNEXIS.com. Replays of each presentation will be available approximately two hours after each event and will be available for two weeks following the presentations.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212.203.4433 [email protected]
